Recent Company News

• 06:57 AM ET Oct 30, 2025
  

  Transcript Intelligence: Astellas Pharma Q2 Earnings Guidance (¥1600.0000, 0)

• 06:57 AM ET Oct 30, 2025
  

  Transcript Intelligence: Astellas Pharma Q2 Earnings Themes (¥1600.0000, 0)

• 06:56 AM ET Oct 30, 2025
  

  Transcript Intelligence: Astellas Pharma Q2 Earnings Q&A (¥1600.0000, 0)

• 02:44 AM ET Oct 30, 2025
  

  Astellas Pharma reports Q2 core profit ¥106.7B vs FactSet ¥96.60B (¥1600.0000, 0)

• 01:32 PM ET Oct 24, 2025
  

  Bayer AG issues press release on previously disclosed FDA approval of Lynkuet (elinzanetant) to treat hot flashes; expected to be available in the U.S. beginning in November 2025 (€27.78, 0.00)

• 01:13 PM ET Oct 24, 2025
  

  FDA approves Bayer's Lynkuet (elinzanetant) to treat hot flashes (€27.78, 0.00)

• 09:41 PM ET Oct 23, 2025
  

  Transcript Intelligence: Astellas Pharma at AACR NCI EORTC International Conference (¥1634.0000, -1)

• 06:04 AM ET Oct 23, 2025
  

  FDA grants Priority Review for Merck's KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Padcev (enfortumab vedotin-ejfv), for certain patients with muscle-invasive bladder cancer ($87.61, 0.00)

• 08:06 AM ET Oct 22, 2025
  

  Astellas preliminary real-world VEOZAH (fezolinetant) data from OPTION-VMS Ph4 observational study meets primary endpoint (¥1623.0000, 0)

• 07:40 PM ET Oct 21, 2025
  

  FDA accepts sBLA for Astellas Pharma's PADCEV in combination with KEYTRUDA for priority review (¥1622.0000, 0)